CoChat

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism

Open access
Krasner, Nadia M., Ido, Yasuo, Ruderman, Neil B., Cacicedo, Jose M. · 2014 · PLoS ONE

Abstract

Liraglutide is a glucagon-like peptide-1 (GLP-1) mimetic used for the treatment of Type 2 diabetes. Similar to the actions of endogenous GLP-1, liraglutide potentiates the post-prandial release of insulin, inhibits glucagon release and increases satiety. Recent epidemiological studies and clinical trials have suggested that treatment with GLP-1 mimetics may also diminish the risk of cardiovascular disease in diabetic patients. The mechanism responsible for this effect has yet to be determined; however, one possibility is that they might do so by a direct effect on vascular endothelium. Since low grade inflammation of the endothelium is an early event in the pathogenesis of atherosclerotic cardiovascular disease (ASCVD), we determined the effects of liraglutide on inflammation in cultured human aortic endothelial cells (HAECs). Liraglutide reduced the inflammatory responses to TNFα and LPS stimulation, as evidenced by both reduced protein expression of the adhesion molecules VCAM-1 and E-Selectin, and THP-1 monocyte adhesion. This was found to result from increased cell Ca2+ and several molecules sensitive to Ca2+ with known anti inflammatory actions in endothelial cells, including CaMKKβ, CaMKI, AMPK, eNOS and CREB. Treatment of the cells with STO-609, a CaMKK inhibitor, diminished both the activation of AMPK, CaMKI and the inhibition of TNFα and LPS-induced monocyte adhesion by liraglutide. Likewise, expression of an shRNA against AMPK nullified the anti-inflammatory effects of liraglutide. The results indicate that liraglutide exerts a strong anti-inflammatory effect on HAECs. They also demonstrate that this is due to its ability to increase intracellular Ca2+ and activate CAMKKβ, which in turn activates AMPK.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0097554

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Liraglutide (100 nM) prevents the inflammatory effects (increases in cellular adhesion molecules) induced by TNFα (10 ng/mL) and LPS (2 µg/mL) in HAECs. (A, B) HAECs were pre-incubated for 1 hr with liraglutide and then co-incubated for 3 hrs with TNFα (A, B) or LPS (C, D) to induce VCAM-1 and E-Selectin protein expression, (n = 6). Anova with Tukey post tests, *p<0.05, **p<0.01, ***p<0.001.
Figure 1 Liraglutide (100 nM) prevents the inflammatory effects (increases in cellular adhesion molecules) induced by TNFα (10 ng/mL) and LPS (2 µg/mL) in HAECs. (A, B) HAECs were pre-incubated for 1 hr with liraglutide and then co-incubated for 3 hrs with TNFα (A, B) or LPS (C, D) to induce VCAM-1 and E-Selectin protein expression, (n = 6). Anova with Tukey post tests, *p<0.05, **p<0.01, ***p<0.001.CC BY · PubMed Central
Figure 2 Liraglutide (100 µM) prevents TNFα and LPS induced monocyte adhesion. HAECs were pre-incubated as described in Fig.1 with liraglutide for 1 hour and, then co-incubated with either 10 ng/mL TNFα or 2 µg/mL LPS for 3 hrs. Fluorescent labeled THP-1 monocytes were then added and the incubation carried out for an additional 30 minutes. Liraglutide prevents (A) TNFα (n = 6) and (C) LPS (n = 8) stimulated monocyte adhesion. B,D: Representative Photomicrographs of HAECs treated as in (A and C) with adhered monocytes (visible as black dots) (10× magnification). *p<0.05, **p<0.01, ***p<0.001.
Figure 2 Liraglutide (100 µM) prevents TNFα and LPS induced monocyte adhesion. HAECs were pre-incubated as described in Fig.1 with liraglutide for 1 hour and, then co-incubated with either 10 ng/mL TNFα or 2 µg/mL LPS for 3 hrs. Fluorescent labeled THP-1 monocytes were then added and the incubation carried out for an additional 30 minutes. Liraglutide prevents (A) TNFα (n = 6) and (C) LPS (n = 8) stimulated monocyte adhesion. B,D: Representative Photomicrographs of HAECs treated as in (A and C) with adhered monocytes (visible as black dots) (10× magnification). *p<0.05, **p<0.01, ***p<0.001.CC BY · PubMed Central
Figure 3 Liraglutide (100 nM) significantly increases intracellular calcium. Prior to the addition of liraglutide, HAECs were incubated with Fura-2, an indicator of intracellular calcium (See methods for details), n = 21 for all results shown. A: HAECs were exposed to 100 nM liraglutide where indicated by the arrow and tracked for 800 seconds. B: Bar graph shows intracellular calcium levels prior to 100 nM liraglutide treatment, (baseline is an average of 6 readings 236–256 seconds) and at peak intracellular calcium subsequently achieved (628–648 seconds) after its addition. C: Cells were tracked for 2000 seconds when 1 uM ionomycin was added to release all intracellular calcium from stores in the endoplasmic reticulum. D: Incubation with a supra-physiological level of liraglutide (2500 nM) caused a greater increase in cell calcium, indicating a possible dose effect for this therapy.
Figure 3 Liraglutide (100 nM) significantly increases intracellular calcium. Prior to the addition of liraglutide, HAECs were incubated with Fura-2, an indicator of intracellular calcium (See methods for details), n = 21 for all results shown. A: HAECs were exposed to 100 nM liraglutide where indicated by the arrow and tracked for 800 seconds. B: Bar graph shows intracellular calcium levels prior to 100 nM liraglutide treatment, (baseline is an average of 6 readings 236–256 seconds) and at peak intracellular calcium subsequently achieved (628–648 seconds) after its addition. C: Cells were tracked for 2000 seconds when 1 uM ionomycin was added to release all intracellular calcium from stores in the endoplasmic reticulum. D: Incubation with a supra-physiological level of liraglutide (2500 nM) caused a greater increase in cell calcium, indicating a possible dose effect for this therapy.CC BY · PubMed Central
Figure 4 Western blot analyses of calcium sensitive and anti-inflammatory enzymes, 1–25 minutes following stimulation by 100 nM liraglutide. These graphs show the effects of liraglutide on the phosphorylation of pCaMK1 (Thr177), pAMPK (Thr172), PACC (S79) peNOS (Ser1177) and pCREB (Ser133) (n = 6) p<0.05, **p<0.01, ***p<0.001.
Figure 4 Western blot analyses of calcium sensitive and anti-inflammatory enzymes, 1–25 minutes following stimulation by 100 nM liraglutide. These graphs show the effects of liraglutide on the phosphorylation of pCaMK1 (Thr177), pAMPK (Thr172), PACC (S79) peNOS (Ser1177) and pCREB (Ser133) (n = 6) p<0.05, **p<0.01, ***p<0.001.CC BY · PubMed Central
Figure 5 STO-609 inhibits liraglutide signaling and its effects on monocyte adhesion. Cells were incubated with STO-609 for 30 minutes prior to addition of liraglutide: A: pAMPK (Thr172), (n = 4) B: pCamK1 (Thr177), (n = 4) C, D: TNFα and LPS stimulated monocyte adhesion (n = 8). Liraglutide: 100 nM, STO-609∶0.5 µg/mL, TNFα: 10 ng/mL, LPS: 2 µg/mL. *p<0.05, **p<0.01, ***p<0.001.
Figure 5 STO-609 inhibits liraglutide signaling and its effects on monocyte adhesion. Cells were incubated with STO-609 for 30 minutes prior to addition of liraglutide: A: pAMPK (Thr172), (n = 4) B: pCamK1 (Thr177), (n = 4) C, D: TNFα and LPS stimulated monocyte adhesion (n = 8). Liraglutide: 100 nM, STO-609∶0.5 µg/mL, TNFα: 10 ng/mL, LPS: 2 µg/mL. *p<0.05, **p<0.01, ***p<0.001.CC BY · PubMed Central
Figure 6 shAMPK knocks down AMPK and inhibits the effects of liraglutide on AMPK and ACC phosphorylation, and monocyte adhesion. A: AMPK phosphorylation (Thr172) B: ACC phosphorylation (Ser79). C,D: Infection of HAECs with shAMPK inhibited the liraglutide induced decrease in TNFα (10 ng/mL) and LPS (2 µg/mL ) stimulated monocyte adhesion (n = 6). *p<0.05, **p<0.01, ***p<0.001.
Figure 6 shAMPK knocks down AMPK and inhibits the effects of liraglutide on AMPK and ACC phosphorylation, and monocyte adhesion. A: AMPK phosphorylation (Thr172) B: ACC phosphorylation (Ser79). C,D: Infection of HAECs with shAMPK inhibited the liraglutide induced decrease in TNFα (10 ng/mL) and LPS (2 µg/mL ) stimulated monocyte adhesion (n = 6). *p<0.05, **p<0.01, ***p<0.001.CC BY · PubMed Central
Figure 7 Schema depicting the proposed mechanisms for the anti-inflammatory effect of liraglutide on human aortic endothelial cells.
Figure 7 Schema depicting the proposed mechanisms for the anti-inflammatory effect of liraglutide on human aortic endothelial cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 187

Metadata

Authors
Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M.
Affiliations
Boston University (US)
Corresponding author
Krasner, Nadia M.
Venue
PLoS ONE
Published
2014-05-16
Volume
9
Issue
5
Pages
e97554
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2008026539
Cited by
186
References
57
Citations by year
2026: 16 · 2025: 21 · 2024: 13 · 2023: 14 · 2022: 12 · 2021: 13 · 2020: 8 · 2019: 22 · 2018: 11 · 2017: 19 · 2016: 18 · 2015: 15 · 2014: 3
FWCI
14.74
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • American Heart Association
  • National Institutes of Health (NHLBI T32, HL068758)
  • National Heart, Lung, and Blood Institute (PO1 HL068758, P01HL068758, HL07969, T32HL007969)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R24DK094749)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
Keywords
liraglutide, GLP-1 receptor agonists, endothelial inflammation, aortic endothelial cells, intracellular calcium, AMPK, CaMKKβ, CaMKI, endothelial nitric oxide synthase, CREB, TNF-α, lipopolysaccharide, monocyte adhesion, VCAM-1, E-selectin, atherosclerotic cardiovascular disease, type 2 diabetes, cardiovascular risk
MeSH terms
Liraglutide, Analysis of Variance, Benzimidazoles, Calcium, Cells, Cultured, Endothelium, Vascular, Humans, Immunoenzyme Techniques, Inflammation, Blotting, Western, RNA Interference, RNA, Small Interfering, Endothelial Cells, Glucagon-Like Peptide 1, Naphthalimides, Calcium-Calmodulin-Dependent Protein Kinase Kinase, Incretins, AMP-Activated Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism. https://app.cochat.ai/papers/10.1371/journal.pone.0097554
The paper
Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014). Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism. PLoS ONE. https://doi.org/10.1371/journal.pone.0097554

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.